Rain Therapeutics Inc. announced the appointments of Stefani Wolff to the board of directors and Simon N. Powell, M.D., Ph.D. to the scientific advisory board. Ms. Wolff has over 33 years of experience in the biopharmaceutical industry and joins the Rain team from Principia Biopharma, where she served as chief development officer and formerly senior vice president of strategy and operations. Dr. Powell is the Enid A. Haupt professor and chairman of the Department of Radiation Oncology at the Memorial Sloan Kettering Cancer Center. He is also a member of the Molecular Biology Program of the Sloan-Kettering Institute, and Weill Cornell Graduate School of Medical Sciences. His primary interests are DNA repair, breast cancer, cancer specific defects in DNA repair and the DNA damage response pathway. Dr. Powell has deep expertise specifically on the role of RAD52 in mediating the DNA damage response pathway, where his lab is one of the leading research centers in the field, and Dr. Powell has co-authored several peer-reviewed publications elucidating the potential of RAD52 as a therapeutic target for cancers characterized by BRCA1/2 deficiencies.